Table 2 Demographic and clinical data of all study participants.
| No | Age (years) | Eye | Underlying diseases | Group | Visual acuity | Change in FFA score* | Systemic treatment | ||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 6 months | Baseline | 6 months | ||||||
| 1 | 61 | LE | None | M | 20/60 | 20/60 | 0 | None | None |
| 2 | 45 | RE | Sarcoidosis | M | 20/60 | 20/200 | steroids | steroids† | |
| 3 | 50 | RE | MS | M | CF | CF | steroids | None | |
| 4 | 35 | RE | None | M | 20/200 | 20/200 | 0 | None | None |
| 5 | 31 | LE | None | M | 20/40 | 20/80 | steroids | None | |
| 6 | 51 | RE | None | M | 20/40 | 20/40 | 0 | None | None |
| 7 | 57 | RE | None | M | 20/200 | 20/200 | 0 | None | None |
| 8 | 47 | LE | None | M | 20/200 | 20/200 | 1 | steroids | steroids† |
| 9 | 29 | RE | None | M | HM | CF | steroids | steroids† | |
| 10 | 55 | RE | None | M | 20/80 | 20/30 | −1 | None | None |
| 11 | 30 | LE | None | M | 20/200 | 20/80 | 1 | None | Aciclovir |
| 12 | 49 | RE | None | S | 20/80 | 20/60 | −1 | steroids/CsA | steroids↓ |
| 13 | 70 | RE | None | S | 10/600 | 20/120 | 0 | None | None |
| 14 | 54 | LE | None | S | CF | 20/80 | 0 | CsA | None |
| 15 | 44 | LE | None | S | 20/60 | 20/40 | 0 | steroids/CsA | steroids/CsA |
| 16 | 49 | RE | Leishmaniasis | S | 20/60 | 20/30 | −1 | steroids/Aza | steroids/Aza |
| 17 | 52 | RE | Sarcoidosis | S | 20/80 | 20/40 | 0 | None | None |
| 18 | 20 | LE | None | S | CF | 20/40 | 0 | None | None |
| 19 | 50 | RE | MS | S | 20/200 | 20/200 | 0 | None | None |
| 20 | 33 | RE | SA | S | 20/200 | 20/200 | −2 | None | None |
| 21 | 41 | LE | None | S | 20/60 | 20/60 | 0 | None | None |
| 22 | 54 | RE | None | S | 20/80 | 20/40 | −1 | None | None |
| 23 | 50 | RE | None | S | 20/120 | 20/120 | 1 | Aza | Aza |
FFA, fundus fluorescein angiogram; MS, multiple sclerosis; SA, seronegative arthritis; CF, counting fingers; HM, hand motion; CsA, ciclosporin A; Aza, azathioprine
*FFA score = score at 6 months − baseline score.
†Reduction in dose.